Kết quả bước đầu hóa xạ trị đồng thời phác đồ Paclitaxel-Carboplatin trong ung thư phổi không tế bào nhỏ giai đoạn III không phẫu thuật=Initial results of concurrent chemoradiotherapy with Paclitaxel-Carboplatin regimen in stage III unresectable non-small cell lung cancer

0 Người đánh giá. Xếp hạng trung bình 0

Tác giả: Thị Thía Đặng, Thanh Bình Lương, Thị Thanh Nhàn Phạm

Ngôn ngữ: vie

Ký hiệu phân loại:

Thông tin xuất bản: Tạp chí Y học Việt Nam (Tổng hội Y học Việt Nam), 2024

Mô tả vật lý: tr.141-146

Bộ sưu tập: Metadata

ID: 245923

Thêm vào giỏ

Đánh giá kết quả điều trị ung thư phổi không tế bào nhỏ giai đoạn III không phẫu thuật bằng phác đồ hóa chất Paclitaxel-Carboplatin kết hợp xạ trị đồng thời và mô tả một số tác dụng không mong muốn của phác đồ này. Đối tượng và phương pháp nghiên cứu: Nghiên cứu mô tả hồi cứu 39 bệnh nhân ung thư phổi không tế bào nhỏ giai đoạn III không phẫu thuật được điều trị hóa chất Paclitaxel-Carboplatin kết hợp xạ trị đồng thời tại Bệnh viện Hữu nghị Việt Tiệp từ tháng 9/2021 đến tháng 9/2023. Kết quả: Tuổi trung bình là 64±8,8, nam giới chiếm 87,2%. Giai đoạn IIIB chiếm tỷ lệ cao nhất là 43,6%, mô bệnh học chủ yếu là carcinoma tuyến chiếm 69,2%. Tỷ lệ đáp ứng toàn bộ là 71,8%, kiểm soát bệnh đạt 89,7%. Trung vị thời gian sống thêm không tiến triển là 11,3 tháng. Có 15,4% bệnh nhân hạ bạch cầu trung tính độ 3, 4. Các tác dụng không mong muốn ngoài hệ tạo huyết chủ yếu ở độ 1, 2: 33,4% viêm phổi, 30,8% viêm thực quản. Kết luận: Hóa xạ đồng thời với phác đồ Paclitaxel-Carboplatin cho thấy tính an toàn và hiệu quả.To evaluate the treatment results of non-surgical of Paclitaxel-Carboplatin regimen combined with concurrent radiotherapy and describe some undesirable effects of this regimen. Patients and methods: Retrospective study on 39 stage III unresectable non-small cell lung cancer patients who received chemotherapy and radiotherapy concurrent with Paclitaxel-Carboplatin at Viet Tiep Hospital from September 2021 to September 2023. Results: Mean age 64±8,8, men account for 87,2%. Stage IIIB accounts for the highest rate of 43,6%. Histopathology is mainly adenocarcinoma, accounting for 69,2%. Overall response rate was 71,8%, disease control rate was 89,7%. Median progression-free survival time was 11,3 months. There were 15,4% of patients with grade 3 and 4 neutropenia. Undesirable effects outside the hematopoietic system were mainly at grades 1 and 2: 33,4% pneumonia, 30,8% esophagitis. Conclusion: Concurrent radiotherapy with Paclitaxel-Carboplatin regimen showed safety and effectiveness.

1. Đọc trực tuyến

1. Đọc trực tuyến

Tạo bộ sưu tập với mã QR